Kyrgyz Republic updates vital-product lists as pharmaceutical manufacturing plans take shape

Verified facts

• Cabinet of Ministers Resolution No. 670 of 6 October 2026 approved national lists of vital medicines and medical devices for 2026 to 2028. The resolution identifies current health-product priorities, but does not establish registration, procurement, reimbursement, import permission, product demand or supplier eligibility for a specific medicine or device.
• The Kyrgyz Republic e-licensing portal identifies the Department of Medicines and Medical Devices under the Ministry of Health as the competent body for state registration of medical devices. Its published route cites the 2017 Law on the Circulation of Medical Devices and Government Resolution No. 311. The procedure must be tested against the exact device, manufacturer, risk class, applicant and current dossier requirements before an offer, sample or shipment is planned.
• The Ministry of Justice legal database records Cabinet Resolution No. 541 of 12 August 2026 approving a procedure for state registration of medicines for medical use. This provides a current regulatory reference, not an individual registration outcome or an authorisation to supply.
• The National Investment Agency reported on 29 September 2026 that it and 21st Century Biomedicine signed a memorandum for a proposed pharmaceutical industrial park. The Agency describes a concept aimed at domestic production and export growth. The memorandum does not confirm finance, land, construction, GMP status, operating capacity, product approval, purchaser access or a commercial appointment.
• The European Observatory identifies mandatory insurance, defined publicly covered services and material out-of-pocket spending in its Kyrgyzstan health-system summary. This independent context supports affordability and purchaser research, but does not identify a current hospital budget, reimbursement decision or transaction.